Should I buy or sell Cytosorbents stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTSO shares. View CTSO analyst ratings or view top-rated stocks .

What is Cytosorbents' stock price target for 2024?

2 Wall Street research analysts have issued 12 month price targets for Cytosorbents' stock. Their CTSO share price targets range from $1.00 to $4.00. On average, they predict the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 212.1% from the stock's current price. View analysts price targets for CTSO or view top-rated stocks among Wall Street analysts .

How have CTSO shares performed in 2024?

Cytosorbents' stock was trading at $1.11 at the start of the year. Since then, CTSO stock has decreased by 27.8% and is now trading at $0.8010. View the best growth stocks for 2024 here .

When is Cytosorbents' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our CTSO earnings forecast .

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) issued its earnings results on Thursday, March, 14th. The medical research company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. The medical research company earned $8.67 million during the quarter, compared to analysts' expectations of $9.29 million. Cytosorbents had a negative trailing twelve-month return on equity of 120.24% and a negative net margin of 78.43%.

What is Phillip Chan's approval rating as Cytosorbents' CEO?

11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com . Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend.

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include Rekor Systems (REKR) , Advanced Micro Devices (AMD) , Micron Technology (MU) , Gilead Sciences (GILD) , Pfizer (PFE) , AbbVie (ABBV) , Inovio Pharmaceuticals (INO) , OPKO Health (OPK) and Sorrento Therapeutics (SRNE) .

Who are Cytosorbents' major shareholders?

Cytosorbents' stock is owned by many different retail and institutional investors. Top institutional investors include Key Client Fiduciary Advisors LLC (0.06%). Insiders that own company stock include Al Kraus, Alan D Sobel, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch , Michael G Bator, Phillip P Chan and Vincent Capponi. View institutional ownership trends .

How do I buy shares of Cytosorbents?

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CTSO

Cytosorbents (CTSO) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

Free CTSO Stock Alerts

$0.80

+0.01 (+1.26%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.79
▼
$0.85
50-Day Range: $0.79
▼
$1.04
52-Week Range: $0.78
▼
$4.29

Volume: 101,761 shs
Average Volume: 159,093 shs
Market Capitalization: $43.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.50

Get Cytosorbents alerts:

Cytosorbents MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 212.1% Upside
$2.50 Price Target
Short Interest: Bearish
2.98% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.36) to ($0.17) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.13 out of 5 stars

Medical Sector

765th out of 918 stocks

Surgical & Medical Instruments Industry

75th out of 91 stocks

3.3

Analyst's Opinion

Consensus Rating
Cytosorbents has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Cytosorbents has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.98% of the outstanding shares of Cytosorbents have been sold short.
Short Interest Ratio / Days to Cover
Cytosorbents has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Cytosorbents has recently decreased by 2.99%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Cytosorbents does not currently pay a dividend.
Dividend Growth
Cytosorbents does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CTSO.

2.5

News and Social Media Coverage

News Sentiment
Cytosorbents has a news sentiment score of 1.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Cytosorbents this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for CTSO on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Cytosorbents to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cytosorbents insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.10% of the stock of Cytosorbents is held by insiders.
Percentage Held by Institutions
Only 32.87% of the stock of Cytosorbents is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cytosorbents are expected to grow in the coming year, from ($0.36) to ($0.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cytosorbents is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cytosorbents is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cytosorbents has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Cytosorbents Stock (NASDAQ:CTSO)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

CTSO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CTSO Stock News Headlines

April 17, 2024 | finance.yahoo.com

STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting

April 8, 2024 | americanbankingnews.com

Brokers Offer Predictions for Cytosorbents Co.'s Q1 2024 Earnings (NASDAQ:CTSO)

April 19, 2024 | Darwin (Ad)

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)

April 4, 2024 | finance.yahoo.com

CTSO: CytoSorbents Expects Significant Gross Margin Expansion in 2024.

April 4, 2024 | finance.yahoo.com

CTSO: CytoSorbents Expects Significant Gross Margin Expansion in 2023.

March 16, 2024 | finance.yahoo.com

Cytosorbents Full Year 2023 Earnings: Misses Expectations

March 16, 2024 | finance.yahoo.com

CTSO Apr 2024 2.500 call

March 15, 2024 | finance.yahoo.com

Q4 2023 Cytosorbents Corp Earnings Call

April 19, 2024 | Darwin (Ad)

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

March 15, 2024 | finance.yahoo.com

Cytosorbents Corporation (NASDAQ:CTSO) Q4 2023 Earnings Call Transcript

March 14, 2024 | benzinga.com

Recap: CytoSorbents Q4 Earnings

March 14, 2024 | globenewswire.com

CytoSorbents Reports Fourth Quarter and Full Year 2023 Results

March 13, 2024 | markets.businessinsider.com

Cytosorbents earnings preview: what to expect

March 6, 2024 | globenewswire.com

CytoSorbents to Report Fiscal 2023 Operating and Financial Results

March 4, 2024 | finance.yahoo.com

CTSO Mar 2024 2.500 call

February 27, 2024 | money.usnews.com

Cytosorbents Corp

February 23, 2024 | finance.yahoo.com

Cytosorbents (NASDAQ:CTSO) investors are sitting on a loss of 90% if they invested three years ago

February 22, 2024 | benzinga.com

CytoSorbents Stock (NASDAQ:CTSO) Insider Trades

February 22, 2024 | benzinga.com

CytoSorbents Stock (NASDAQ:CTSO) Dividends: History, Yield and Dates

February 8, 2024 | finance.yahoo.com

CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference

January 17, 2024 | finance.yahoo.com

CTSO: CytoSorbents reports update on data results from important U.S. and Canadian STAR-T pivotal trial.

January 17, 2024 | finance.yahoo.com

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

January 6, 2024 | stockhouse.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

December 30, 2023 | msn.com

HC Wainwright & Co. Downgrades Cytosorbents (CTSO)

December 30, 2023 | markets.businessinsider.com

CytoSorbents Holds Steady with Neutral Rating Amid Clinical and Financial Reassessments

December 29, 2023 | realmoney.thestreet.com

CytoSorbents just downgraded at H.C. Wainwright, here's why

December 29, 2023 | markets.businessinsider.com

What To Know About HC Wainwright & Co.'s Downgrade of CytoSorbents

See More Headlines

Receive CTSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:CTSO
CUSIP: N/A
CIK: 1175151
Web: www.cytosorbents.com
Phone: (732) 329-8885
Fax: 732-329-8650
Employees: 186
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.50
High Stock Price Target: $4.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +212.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,510,000.00
Net Margins: -78.43%
Pretax Margin: -80.67%
Return on Equity: -120.24%
Return on Assets: -54.11%

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 1.77
Quick Ratio: 1.51

Sales & Book Value

Annual Sales: $36.35 million
Price / Sales: 1.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.52 per share
Price / Book: 1.54

Miscellaneous

Outstanding Shares: 54,290,000
Free Float: 49,896,000
Market Cap: $43.49 million
Optionable: Optionable
Beta: 0.58

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Phillip P. Chan M.D. (Age 54)
Ph.D., CEO & Director
Comp: $541.93k
Mr. Vincent J. Capponi M.S. (Age 66)
President & COO
Comp: $452.62k
Ms. Kathleen P. Bloch CPA (Age 69)
M.B.A., Chief Financial Officer
Comp: $395.43k
Dr. Efthymios N. Deliargyris FACC (Age 56)
FESC, FSCAI, M.D., Chief Medical Officer
Comp: $463.15k
Ms. Terri Anne Powers M.B.A.
Vice President of Investor Relations & Corporate Communications
Dr. Christian Steiner M.D.
Executive Vice President of Sales & Marketing
Mr. Christopher Cramer M.B.A.
M.S., Senior Vice President of Business Development
Dr. Irina B. Kulinets Ph.D. (Age 69)
Senior Vice President of Global Regulatory Affairs
Jodi Hoover
Executive
Dr. Robert H. Bartlett M.D. (Age 85)
Co-Chairman of Cardiac Surgery Advisory Board & Consultant
Comp: $54k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CTSO Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytosorbents stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTSO shares.
View CTSO analyst ratings or view top-rated stocks.
What is Cytosorbents' stock price target for 2024?: 2 Wall Street research analysts have issued 12 month price targets for Cytosorbents' stock. Their CTSO share price targets range from $1.00 to $4.00. On average, they predict the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 212.1% from the stock's current price.
View analysts price targets for CTSO or view top-rated stocks among Wall Street analysts.
How have CTSO shares performed in 2024?: Cytosorbents' stock was trading at $1.11 at the start of the year. Since then, CTSO stock has decreased by 27.8% and is now trading at $0.8010.
View the best growth stocks for 2024 here.
When is Cytosorbents' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our CTSO earnings forecast.
How were Cytosorbents' earnings last quarter?: Cytosorbents Co. (NASDAQ:CTSO) issued its earnings results on Thursday, March, 14th. The medical research company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. The medical research company earned $8.67 million during the quarter, compared to analysts' expectations of $9.29 million. Cytosorbents had a negative trailing twelve-month return on equity of 120.24% and a negative net margin of 78.43%.

What is Phillip Chan's approval rating as Cytosorbents' CEO?: 11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend.
What other stocks do shareholders of Cytosorbents own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).
Who are Cytosorbents' major shareholders?: Cytosorbents' stock is owned by many different retail and institutional investors. Top institutional investors include Key Client Fiduciary Advisors LLC (0.06%). Insiders that own company stock include Al Kraus, Alan D Sobel, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi.
View institutional ownership trends.
How do I buy shares of Cytosorbents?: Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTSO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial